Recursion Pharmaceuticals

Recursion Pharmaceuticals

Yahoo Finance • 6 days ago

Most shorted stocks on Wall Street

[short sale] abluecup As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of shares outstan... Full story

Yahoo Finance • 23 days ago

FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug

AstraZeneca AZN announced that the FDA accepted its regulatory filing seeking approval for its investigational enzyme replacement therapy (ERT) efzimfotase alfa to treat patients aged two years and older with hypophosphatasia (HPP). The F... Full story

Yahoo Finance • 30 days ago

Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk

[Reciprocal Tariffs] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - SEPTEMBER 14 * VOLATILIT... Full story

Yahoo Finance • last month

FDA names acting heads of drug and vaccine units to permanent roles

[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House advisor Heidi Overton as the agency's nex... Full story

Yahoo Finance • last month

Catalyst watch: Apple's high-stakes iPhone event, Oracle, CPI, and the NFL returns

[New York Stock Exchange pediment carving] Jean Suplicy Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. M... Full story

Yahoo Finance • 2 months ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 2 months ago

Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Update

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recursion Pharmaceuticals stock has had a difficult run over the past several years, and the cur... Full story

Yahoo Finance • 2 months ago

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026, the Compensation Committee of Recursio... Full story

Yahoo Finance • 3 months ago

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

Issued on behalf of MindWalk Holdings Corp. (NASDAQ: HYFT) AUSTIN, Texas, July 24, 2026 /PRNewswire/ -- American News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely... Full story

Yahoo Finance • 3 months ago

Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?

In Cathie Wood's Ark Genomic Revolution ETF (NYSEMKT: ARKG), as of July 10, the three top holdings are Tempus AI, 10x Genomics, and Twist Bioscience. But digging past the top 10 holdings, there's a $1.8 billion biotech company with a growi... Full story

Yahoo Finance • 3 months ago

Cathie Wood reshuffles portfolio ahead of Q2, buys SpaceX, Eli Lilly, Meta; pares AMD, Roku

Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52... Full story

Yahoo Finance • 3 months ago

Cathie Wood buys $22.8 million of surging tech stock

Cathie Wood, CEO of Ark Investment Management, is known for investing in high-growth tech companies. She'll even add to positions amid strong gains, and that's what she just did, adding shares of a megacap stock that has surged 14.8% over... Full story

Yahoo Finance • 3 months ago

2 Beaten-Down Stocks That Still Aren't Worth Buying

Buying shares of excellent companies that have fallen out of favor is a great way to earn superior returns over the long run. However, investors should be careful not to catch a falling knife. Corporations often fail to keep up with broade... Full story

Yahoo Finance • 3 months ago

Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company that is building an AI-native discovery platform... Full story

Yahoo Finance • 3 months ago

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors. Moderna (NASDAQ:MRNA) and Recursion Pharmaceuticals (NASDAQ:RXRX... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against the specific clinical prospects of a high-potential oncology drug candi... Full story

Yahoo Finance • 3 months ago

Cathie Wood buys $11.5 million of battered tech stock

Cathie Wood, chief of Ark Investment Management, likes to double down on her favorite tech stocks when the prices are falling, hoping for a bargain. That's what Wood just did, adding shares of Coinbase after weeks of tumbling. In 2025, W... Full story

Yahoo Finance • 3 months ago

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market

Key Points Artificial intelligence technology giant Nvidia owns a handful of promising stocks. One of these holdings is helping lead the charge of change for an industry that could use a cost-reducing revamp. Although this name poses abov... Full story

Yahoo Finance • 4 months ago

2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying

Key Points Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds. 10 stocks we like better than Recursion Pharmaceutica... Full story

Yahoo Finance • 5 months ago

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?

Key Points Recursion Pharmaceuticals is using AI to improve how we develop drugs. The company has partnered with several major corporations in this quest. The biotech has yet to show meaningful results from its approach. 10 stocks we lik... Full story